T h e ne w e ngl a nd jou r na l o f m e dicine S ince its successful introduction in 1978, in vitro fertilization (IVF) has traditionally been performed by the transfer of fresh embryos. In the first decades of IVF, the use of ovarian hyperstimulation allowed for the development and transfer of multiple embryos. 1 As IVF technology improved, the number of multiple pregnancies increased, which led to a gradual reduction in the number of embryos that were transferred. 2 Embryo freezing was performed to allow subsequent transfer if the fresh cycle was unsuccessful. The results of small randomized trials suggested that freezing all embryos in a fresh IVF cycle followed by thawed frozen transfer in subsequent cycles (frozen-embryo transfer) might improve pregnancy rates. 3, 4 Also, it has been suggested that pregnancies occurring after frozen-embryo transfer are associated with fewer complications (e.g., lower rates of antepartum hemorrhage) and better neonatal outcomes, including higher birth weight and lower risk of perinatal death. 5 Frozen-embryo transfer has become increasingly common, with the number of frozen cycles increasing in many countries. 6 In a recent multicenter, randomized trial involving infertile women with the polycystic ovary syndrome who were undergoing IVF in China, those who received frozen embryos had a significantly higher rate of live birth than did those receiving fresh embryos (49% vs. 42%, P = 0.004). 7 However, questions remain about whether frozenembryo transfer would improve outcomes in infertile women who do not have the polycystic ovary syndrome. We performed a randomized trial comparing the effectiveness of the transfer of frozen embryos versus fresh embryos in infertile women without the polycystic ovary syndrome who were undergoing IVF.
Me thods

Study Design and Oversight
We conducted a single-center, randomized, controlled trial at a private unit at My Duc Hospital in Ho Chi Minh City, Vietnam, which performs approximately 6000 IVF cycles annually. The study was approved by the hospital ethics committee and conducted according to Good Clinical Practice and Declaration of Helsinki 2002 principles, including oversight by an independent data and safety monitoring committee. All the patients provided written informed consent. The study protocol and statistical analysis plan are available with the full text of this article at NEJM.org.
Study Population
Women were eligible if they were infertile, were scheduled for IVF, and had undergone no more than one previous IVF cycle. They were excluded if they had a history of the polycystic ovary syndrome (on the basis of the Rotterdam criteria 8 ), were undergoing in vitro maturation with polycystic ovaries visible on ultrasonography, or had undergone oocyte donation. Women and their partners were provided with oral and written study information at the start of ovarian stimulation.
IVF Treatment
All the women were undergoing controlled ovarian hyperstimulation according to the protocol for the use of follicle-stimulating hormones and gonadotropin-releasing hormone antagonists. The dose of recombinant follicle-stimulating hormone ranged from 150 to 300 IU per day, depending on the woman's age, antimüllerian hormone levels, and response to follicle-stimulating hormone in any prior IVF cycle. Follicular development was monitored by means of ultrasonography, along with testing of estradiol and progesterone levels. When the mean diameter of at least two leading follicles was 17 mm, 250 μg of recombinant human chorionic gonadotropin (Ovitrelle, Merck Serono) was administered, and oocyte retrieval was performed 36 hours later.
Insemination was performed by means of an intracytoplasmic sperm injection that was administered 3 to 4 hours after oocyte retrieval. A fertilization check was performed 16 to 18 hours after insemination. Evaluation and grading of the embryo were performed at a mean (±SD) of 68±1 hours after fertilization with the use of the Istanbul consensus. 
Study Procedures
On day 3 after ovum retrieval (embryo-transfer day), the treating clinicians screened women for eligibility. Women were eligible if they could undergo embryo transfer on day 3, had at least one grade 1 embryo 9 on day 3, and agreed to have a maximum of two embryos transferred. On day 3 after oocyte retrieval, women who met the inclusion criteria were invited to participate in the study. The women were randomly assigned in a 1:1 ratio to receive either fresh embryos or frozen embryos by means of block randomization by an independent study coordinator using a computer-generated random list (with a block size of 2, 4, or 8).
Interventions
In the frozen-embryo group, all grade 1 and 2 embryos had been cryopreserved by means of the Cryotech vitrification method, with a maximum of two embryos per Cryotop. Grade 3 embryos could be cryopreserved at the request of the couple. In the following cycle, the endometrium was prepared with the use of oral estradiol valerate (Valiera, Laboratorios Recalcine) at a dose of 8 mg per day, starting on the second or third day of the menstrual cycle. Endometrial thickness was monitored from day 6 onward, and vaginal progesterone (Cyclogest, Actavis) at a dose of 800 mg per day was started when the endometrial thickness reached 8 mm or more. A maximum of two embryos of grade 1 or 2 were thawed on the day of embryo transfer, 3 days after the start of progesterone. Two hours after thawing, surviving embryos were transferred into the uterus under ultrasonographic guidance. When women had arranged for more than two embryos to be frozen, the procedure was repeated in subsequent cycles if needed.
In the fresh-embryo group, a maximum of two grade 1 or 2 embryos were transferred into the uterus under ultrasonographic guidance on the day of randomization. Any remaining grade 1 or 2 embryos, along with grade 3 embryos (if requested by the couple), were frozen and transferred in subsequent cycles if needed.
Follow-up
Luteal-phase support consisted of 8 mg of oral estradiol and 800 mg of vaginal progesterone per day, starting 3 days before embryo transfer in the frozen-embryo group, or 800 mg of vaginal progesterone, starting on the day of oocyte retrieval in the fresh-embryo group; both drug regimens continued until pregnancy testing was performed. The serum level of beta human chorionic gonadotropin (hCG) was measured 2 weeks after embryo transfer (Cobas, Roche Diagnostics). If the pregnancy test was positive (hCG, >5 mIU per milliliter), luteal-phase support was continued until 7 weeks of gestation, and ultrasonography of the pelvis was performed at gestational weeks 7 and 12. For the remainder of the pregnancy and neonatal period, the women were followed and treated on the basis of routine clinical practice.
Outcomes
The primary outcome was ongoing pregnancy after the first transfer of embryos. Ongoing pregnancy was defined as pregnancy with a detectable heart rate after 12 weeks of gestation. Secondary outcomes were the rates of implantation, clinical pregnancy, ectopic pregnancy, miscarriage, live birth, multiple pregnancy, vanishingtwin pregnancy, and the ovarian hyperstimulation syndrome. (Full definitions of these terms are provided in Table S1 in the Supplementary Appendix, available at NEJM.org.) For pregnancies that continued beyond 24 weeks, we recorded the following complications: pregnancy-induced hypertension, 10 preeclampsia, and the HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome; antepartum hemorrhage; gestational diabetes mellitus 11 ; and obstetrical outcomes, including gestational age at delivery, cesarean section (elective, suspected fetal distress, and nonprogressive labor), vaginal-instrumental delivery, increased peripartum blood loss, birth weight, macrosomia, small size for gestational age, prematurity, admission to a neonatal intensive care unit, perinatal death, and congenital malformations diagnosed at birth (Table  S2 in the Supplementary Appendix). The total duration of follow-up was 12 months, including a post hoc analysis of the ongoing pregnancy rate. Study data were obtained by means of questionnaires, interviews with patients, laboratory testing, and medical records.
Statistical Analysis
Before the initiation of our study, the ongoing pregnancy rate after the transfer of two fresh embryos at our hospital was 30%. To detect a minimally important absolute difference of 10 percentage points in the ongoing pregnancy rate, we determined that a sample size of 780 women (390 per group) would provide a power of 80% at an alpha level of 0.05, with an estimated dropout rate of 10%. After data on the first 400 women were available, one interim analysis was planned and performed with the use of the Haybittle-Peto alpha-spending function, which meant that the final type I error remained at 0.05.
T h e ne w e ngl a nd jou r na l o f m e dicine Analyses were performed on an intention-totreat basis by an independent statistician who had access to all the data. Primary and secondary outcomes were assessed by comparing the outcome after the first embryo transfer. Rates were calculated for dichotomous variables and compared by calculating relative risks and 95% confidence intervals. We used Fisher's exact test to assess between-group differences in noncontinuous variables and Student's t-test to assess differences in continuous variables. No adjustment was made for multiple testing.
The rate of ongoing pregnancy in the two groups at 12 months was determined, and a risk ratio was used to describe the difference. To estimate the cumulative ongoing pregnancy rate over the 12-month follow-up, we constructed and compared Kaplan-Meier curves; a log-rank test, Cox regression model, and hazard ratio were used to describe the difference. We also compared all secondary outcomes for all first ongoing pregnancies that occurred within 12 months. All the analyses were performed with the use of the R statistical package, version 3.3.1. A two-sided P value of less than 0.05 was considered to indicate statistical significance.
R esult s
Study Patients
From June 2015 through April 2016, a total of 3056 women underwent screening, and 949 met the eligibility criteria. Of these women, 152 chose to freeze embryos for delayed transfer. The 782 women who provided informed consent were randomly assigned to the frozen-embryo group or the fresh-embryo group, with 391 patients in each group (Fig. 1) . Additional details regarding the embryo transfers that were performed after randomization are provided in Figure S1 in the Supplementary Appendix. The characteristics of the patients in the study groups at baseline are provided in Table 1 . On the day that oocyte maturation was triggered, there were no significant differences in estradiol and progesterone levels between the overall study population and the patients who chose elective embryo freezing.
After randomization, 9 women in the frozenembryo group opted to undergo transfer of fresh embryos, whereas 10 women in the fresh-embryo group opted to undergo transfer of frozen embryos.
The number of embryos that were frozen was higher in frozen-embryo group than in the freshembryo group (5.1±2.7 vs. 3.8±2.8, P<0.001), since 2 fresh embryos were transferred in most cycles. At 12 months after randomization, 582 transfers had been performed in the frozenembryo group; 391 women had undergone one transfer, 157 had undergone two transfers, 31 had undergone three transfers, and 3 had undergone four transfers. A total of 23 couples had started a second stimulated cycle, and 2 had started a third. In the fresh-embryo group, there had been 391 fresh transfers and 224 frozen transfers; 391 women had undergone one transfer, 172 had undergone two transfers, 45 had undergone three transfers, and 7 had undergone four transfers. A total of 25 couples had started a second cycle, and 3 had started a third. Followup data were complete for all the women in the study.
Primary Outcome
Ongoing pregnancy after the first completed cycle occurred in 142 of 391 women (36.3%) in the frozen-embryo group and in 135 of 391 (34.5%) in the fresh-embryo group, for a betweengroup difference of 1.8 percentage points (95% confidence interval [CI], -5.2 to 8.7; risk ratio, 1.05; 95% CI, 0.87 to 1.27; P = 0.65) ( Table 2) .
Secondary Outcomes
After the first embryo transfer, rates of implantation, clinical pregnancy, and live birth did not differ significantly between the frozen-embryo group and the fresh-embryo group (Table 2) . Live births occurred in 132 women (33.8%) in the frozen-embryo group and in 123 women (31.5%) in the fresh-embryo group, for a betweengroup difference of 2.3 percentage points (95% CI, -4.5 to 9.1; risk ratio, 1.07; 95% CI, 0.88 to 1.31; P = 0.54). There were no significant betweengroup differences in the frequencies of ectopic pregnancy, miscarriage, multiple pregnancy, the ovarian hyperstimulation syndrome in the primary cycle, or pregnancy complications (Tables  2 and 3 ). The proportion of singleton babies that were below the 10th percentile for birth weight was significantly lower in the frozen-embryo group than in the fresh-embryo group (P = 0.01) ( Table 3, 
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Outcomes at 12 Months
In post hoc analyses of outcomes at 12 months, the median time to pregnancy was 3.6 months in the frozen-embryo group and 2.2 months in the fresh-embryo group (absolute difference, 1.4 months; 95% CI, 0.95 to 1.84; P<0.001). The cumulative ongoing pregnancy rate 1 year after randomization was 54.2% in the frozen-embryo group and 53.5% in the fresh-embryo group (hazard ratio, 0.88; 95% CI, 0.73 to 1.07; P = 0.21) (Fig. S3 in the Supplementary Appendix) .
The cumulative 12-month rate of live birth in women who had completed 12 months of follow-up was 48.8% in the frozen-embryo group and 47.3% in the fresh-embryo group (risk ratio, 1.03; 95% CI, 0.89 to 1.19; P = 0.72). Twelvemonth follow-up data for other secondary outcomes are reported in Table 4 , and in Table S4 in the Supplementary Appendix.
Discussion
In our study of infertile women without the polycystic ovary syndrome who were undergoing IVF, those who underwent frozen-embryo transfer did not have significantly higher ongoing pregnancy rates than did those who underwent freshembryo transfer. Also, there was no significant between-group difference in the live-birth rate after the first cycle or at 12 months or in the 12-month rate of ongoing pregnancy.
Factors that limit the generalizability of our results warrant attention. The trial was conducted at a single center in Asia, and the ongoing pregnancy rate was somewhat low according to the standards in some countries (34 to 36% vs. 41.2% for patients <35 years of age, as reported by the Society for Assisted Reproductive Technology in 2014
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). In addition, our results are specific to the Cryotech vitrification method that was used. Although frozen-embryo strategies are growing in popularity, both slow freezing and vitrification are used by clinics worldwide, and this choice could influence the results of any comparison between frozen-embryo transfer and fresh-embryo transfer. 11, 14, 15 Our study included the transfer of two embryos and universal intracytoplasmic sperm injection. These methods reflect the practice across Asia and elsewhere but * Plus-minus values are means ±SD. There were no significant differences between the two groups as calculated by means of the Wilcoxon test and the chi-square test. Percentages may not total 100 because of rounding. IVF denotes in vitro fertilization, and PCOS polycystic ovary syndrome. † The body-mass index is the weight in kilograms divided by the square of the height in meters. ‡ Other indications included advanced maternal age (≥38 years), low ovarian reserve (antimüllerian hormone level, <1.38 ng per milliliter), 12 a history of ectopic pregnancy or hydrosalpinx successfully treated laparoscopically to achieve patent tubes but lack of pregnancy after 6 months, and adenomyosis. § Embryos were rated according to the Istanbul criteria, with "good" being defined as grade I, cell number of 7 to 9, even cell size, less than 10% fragmentation, and no multinucleation. 16 Finally, although clinicians and embryologists were unaware of study-group assignments, practical considerations meant that patients were aware of which treatment they received.
In two previous, smaller randomized trials comparing the transfer of frozen versus fresh embryos, 3, 4 clinical and ongoing pregnancy rates were 15 to 30% higher after the transfer of frozen embryos than after the transfer of fresh embryos, although the presence or absence of the polycystic ovary syndrome was not noted; similar findings were observed in a meta-analysis of 11 observational studies. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] In contrast, our trial did not show significant between-group differences in ongoing pregnancy rates. Similar to the two previous smaller trials, 3, 4 our study used gonadotropin-releasing hormone antagonist protocols for ovarian stimulation, and the distributions of causes of infertility, patient age, and hormone levels on the day of triggering of oocyte maturation were similar; however, the mean body-mass index was lower among the women in our trial than in the cited trials. In a recent large, randomized trial comparing frozen-embryo transfer with fresh-embryo transfer in women with the polycystic ovary syndrome who were undergoing IVF with the transfer of two embryos, 7 there was no significant betweengroup difference in the ongoing pregnancy rate, but the live-birth rate was significantly higher with frozen-embryo transfer, owing to a lower rate of pregnancy loss during the second trimester. The frozen-embryo group also had a lower rate of the ovarian hyperstimulation syndrome. 7 Women with the polycystic ovary syndrome are known to have 
Treatment complication
Moderate or severe ovarian hyperstimulation syndrome -no. 
Table 2. Fertility Outcomes and Treatment Complications after the First Embryo Transfer.*
T h e ne w e ngl a nd jou r na l o f m e dicine a higher risk of ovarian hyperstimulation syndrome and of pregnancy complications than are women without this condition and thus may be more likely to benefit from a frozen-embryo strategy. 27 However, our findings are not necessarily inconsistent with those reported in women with the polycystic ovary syndrome, because the 95% confidence intervals around the risk ratios for live birth that were associated with frozen-embryo transfer in our trial overlap with the 95% confidence intervals in that report. 7 Another factor that could contribute to different results among the studies 3,4,7 may be the timing of freezing. We froze embryos on day 3, and the results of freezing may be different after blastocyst transfer, as has been performed in some other studies. 28 In one study, investigators found no significant difference in the ongoing † Small for gestational age was defined as a birth weight below the 10th percentile. ‡ Large for gestational age was defined as a birth weight above the 90th percentile. 
Pregnancy outcomes
Small for gestational age -no. T h e ne w e ngl a nd jou r na l o f m e dicine pregnancy rate between frozen-embryo and freshembryo transfer when blastocysts that had been frozen on day 6 were transferred on day 5 of a freeze-thaw cycle, which suggests that dysynchrony between endometrial and embryo development in the fresh-embryo cycle may explain the lower success rates. 29 In our study, the only significant betweengroup differences in perinatal outcomes were in singleton birth weight (which was lower in the fresh-embryo group) and the proportion of infants who were small for their gestational age (which was higher in the fresh-embryo group.) Of note, the mean birth weight overall was within the normal range. The performance of multiple comparisons increases the likelihood of a significant finding occurring by chance. However, Chen et al. also found that the singleton birth weight was significantly higher in the frozenembryo group than in the fresh-embryo group (between-group difference, 162 g; P<0.005). 7 In a large retrospective Japanese study, frozen transfer was associated with better perinatal outcomes (e.g., preterm birth, small size for gestational age, and low birth weight) than was fresh-embryo transfer, 28 although an increase in the proportion of infants who were large for their gestational age after frozen-embryo transfer has been reported in other observational studies. 20, [30] [31] [32] No significant between-group difference in the rate of congenital abnormalities was identified in a large cohort study. 33 In contrast to the prior trial involving women with the polycystic ovary syndrome, 7 we did not find a significantly lower rate of the ovarian hyperstimulation syndrome in the frozen-embryo group than in the fresh-embryo group. 7 However, the rate of this complication was very low in our trial. Women at high risk for the ovarian hyperstimulation syndrome were not included in our trial, owing to our practice of routinely administering gonadotropin-releasing hormone agonist to trigger oocyte maturation in women with more than 15 follicles on the day of hCG administration to minimize the risk of ovarian hyperstimulation; the use of gonadotropin-releasing hormone agonist was an exclusion criterion for our trial. All three stillbirths in our study occurred in the fresh-embryo group, but the number of events was small.
Although the majority of outcomes in our study did not differ significantly between the two groups, the median time to conception was 1.4 months shorter in the fresh-embryo group. This difference is small but may be a relevant factor for some patients in terms of the overall treatment duration and both the direct and indirect costs of IVF.
In conclusion, we found no significant difference in the rate of ongoing pregnancy or live birth between frozen-embryo transfer and freshembryo transfer in women without the polycystic ovary syndrome who were undergoing IVF.
